banner image

ARE YOU ELIGIBLE FOR CARVYKTI®?

If you have not been prescribed CARVYKTI® yet, you can use this simple tool to find out if you may be eligible for treatment. Answer the questions below to find out if you may be eligible.

Consider the lines of treatment you (or the person you care for) have received to treat multiple myeloma. Has the most recent treatment not worked or stopped working?

How many lines of treatments have you already received?
(This includes treatments such as proteasome inhibitors, immunomodulatory agents, or anti-CD38 antibodies.)

1 line

2 lines

3 lines

4 or more lines

Which of the following types of treatment have you already received?
(Check all that apply)

You may be a candidate for treatment with CARVYKTI®.
Talk to your doctor about CARVYKTI® and whether it's right for you.

There may still be treatment options available that may help control your multiple myeloma before it's time for you and your doctor to consider CARVYKTI®. If your disease returns following 4 or more kinds of treatments, including at least 1 proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody, talk to your doctor to see if CARVYKTI® is an option for you.

At this time, you (or the person you care for) are not a candidate for CARVYKTI®. Please continue consulting with your doctor to learn more about keeping multiple myeloma under control.

THE CARVYKTI® TREATMENT PROCESS

CARVYKTI® (ciltacabtagene autoleucel) is an individualized treatment that is prescribed and infused at a Certified Treatment Center. Your primary oncologist will help you set up a consultation at a Certified Treatment Center, which will determine your eligibility and provide your treatment with CARVYKTI®. You'll still remain in contact and may keep your scheduled appointments with your primary oncologist, who will continue to be involved in your care throughout this process and especially when you return home for longer-term monitoring and follow-up care.

Therapy with CARVYKTI® is a 5-step process that generally takes about 2 to 3 months to complete.*

step_1_treatment_process

STEP 1: CELL COLLECTION

3 TO 6 HOURS

Some of your blood is drawn into a machine that separates the white and red blood cells, collects some of the white blood cells (including T cells), and returns the rest of the blood to your body. This process is called leukapheresis (loo-kuh-fur-ee-sis). This process may take 3 to 6 hours and may need to be repeated.

Between cell collection and pre-infusion treatment, your doctor may prescribe additional therapy to treat your multiple myeloma, often called bridging therapy.

step_2_treatment_process.svg

STEP 2: GENETICALLY MODIFYING YOUR T CELLS

~4 TO 5 WEEKS*

Your white blood cells are sent to a manufacturing site, where the T cells are separated out and customized into your CARVYKTI® CAR-T cells. This is done by genetically modifying your T cells to be able to recognize BCMA on the surface of multiple myeloma cells. Your CARVYKTI® CAR-T cells are then frozen and sent to your CARVYKTI® Certified Treatment Center.

Between cell collection and pre-infusion treatment, your doctor may prescribe additional therapy to treat your multiple myeloma, often called bridging therapy.

step_3_treatment_process

STEP 3: PRE-INFUSION TREATMENT

3 DAYS

A few days before your CARVYKTI® infusion, you’ll receive chemotherapy infusions with cyclophosphamide and fludarabine. These infusions will help prepare your body for the infusion. Each of these infusions will be given to you once a day for 3 days. These infusions are given to help clear out some of your white blood cells to make the necessary space in your immune system for CARVYKTI®. This is also known as lymphodepleting chemotherapy.

step_4_treatment_process

STEP 4: ONE-TIME CARVYKTI® INFUSION

~30 TO 60 MINUTES

About a month after your initial cell collection, and 2 to 4 days after lymphodepleting chemotherapy, you’ll be given your CARVYKTI® through a one-time intravenous infusion that takes approximately 30 to 60 minutes. Your healthcare providers will guide you through what your infusion day will be like.

step_5_treatment_process

STEP 5: MONITORING

4 WEEKS AND BEYOND

After your infusion of CARVYKTI®, your healthcare providers at the CARVYKTI® Certified Treatment Center will closely monitor you daily for 10 days following infusion for any signs and symptoms of a reaction to treatment.

You should plan to stay close to the location where you received your treatment for at least 4 weeks. Your healthcare provider will check to see that your treatment is working and help you with any side effects that may occur. You may be hospitalized if you develop serious side effects until your side effects are under control and it is safe for you to leave the hospital.

Your healthcare provider will want to do blood tests to follow your progress. It is important that you have your blood tested. If you miss an appointment, call your healthcare provider as soon as possible to reschedule. After this 4 week monitoring period, your healthcare providers will continue to provide care and partner with you to create a plan for long-term monitoring and regular follow-ups. Let your healthcare providers know if you're not feeling well. Do not drive, or operate heavy machinery, or do other activities that could be dangerous if you are not mentally alert, for at least 8 weeks after you receive CARVYKTI®. This is because the treatment can cause memory and coordination problems, sleepiness, confusion, dizziness, seizures, or other neurologic side effects as discussed by your healthcare provider.

BCMA=B cell maturation antigen; CAR-T=chimeric antigen receptor T cell.

*Timing and outcomes of manufacturing may vary.

73/97 patients in the CARTITUDE-1 study received bridging therapy.

EXPLORE THE CARVYKTI® TREATMENT PROCESS

Watch this immersive video that guides patients and caregivers through what to expect at each stage of the CARVYKTI® journey.

SEE HOW YOUR CARVYKTI® CAR-T CELLS ARE MADE

PLANNING FOR TREATMENT WITH CARVYKTI®

Traveling away from home for medical care can be financially and logistically challenging. Support is available for eligible patients and their caregivers.

The MyCARVYKTI® Patient Support Program

The MyCARVYKTI® Patient Support Program, sponsored by Janssen Biotech, Inc., and Legend Biotech, is designed to help eligible patients prescribed CARVYKTI® and their caregivers with support during treatment.

Patients who meet financial and other eligibility requirements, and their caregivers, may receive:

curving_road_icon

Assistance with transportation, lodging, and out-of-pocket costs related to meals and other travel expenses associated with treatment at the CARVYKTI® Certified Treatment Center

headphone_icon

Support from MyCARVYKTI® Patient Support Specialists, who are available to help guide eligible patients through the enrollment process and assist with program benefits

TIPS FOR TREATMENT

CAREGIVER TIPS

support_heart_icon

Your role in supporting the person you care for—the encouragement, emotional support, and practical assistance you provide—makes you an important part of the treatment experience.

You may need to help the person you care for with:
  • Monitoring for signs and symptoms of side effects and communicating them to healthcare providers
  • Scheduling appointments
  • Providing transportation to appointments and keeping them company
  • Helping communicate with the healthcare providers (for example, providing medical and insurance information, asking questions)
  • Responsibilities at home
  • Emotional support and having someone to talk with
  • Managing their schedule and letting visitors know if they feel up to seeing them

You don't have to manage this alone. Support is available to help you along the way, and you may want to identify friends or family who can help you as well.